Develops drugs for cancer and inflammatory metabolic diseases.
Mar 2025Revenue $233K/yrExpenses $3.24M/yr
No trendCash runway ≈ 2.0 years from Jun 2026
Figures by year
When will Nexentis Technologies be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2025, revenue was $233K and expenses $3.24M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $210K | $3.49M | −$3.28M |
| Dec 2023 | $263K | $7.84M | −$7.58M |
| Dec 2022 | $394K | $6.21M | −$5.82M |
| Dec 2021 | $438K | $5.14M | −$4.70M |
| Dec 2020 | $232K | $1.58M | −$1.35M |
| Dec 2019 | $176K | $2.11M | −$1.93M |
| Dec 2018 | $427K | $945K | −$519K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.